These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38867886)

  • 1. The interplay between gut microbiota and the brain-gut axis in Parkinson's disease treatment.
    Jia X; Wang Q; Liu M; Ding JY
    Front Neurol; 2024; 15():1415463. PubMed ID: 38867886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis.
    Zhao Z; Ning J; Bao XQ; Shang M; Ma J; Li G; Zhang D
    Microbiome; 2021 Nov; 9(1):226. PubMed ID: 34784980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Interplay between Gut Microbiota and Parkinson's Disease: Implications on Diagnosis and Treatment.
    Varesi A; Campagnoli LIM; Fahmideh F; Pierella E; Romeo M; Ricevuti G; Nicoletta M; Chirumbolo S; Pascale A
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of gut dysbiosis in Parkinson's disease: mechanistic insights and therapeutic options.
    Wang Q; Luo Y; Ray Chaudhuri K; Reynolds R; Tan EK; Pettersson S
    Brain; 2021 Oct; 144(9):2571-2593. PubMed ID: 33856024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysbiosis of the gut microbiota and its effect on α-synuclein and prion protein misfolding: consequences for neurodegeneration.
    Mahbub NU; Islam MM; Hong ST; Chung HJ
    Front Cell Infect Microbiol; 2024; 14():1348279. PubMed ID: 38435303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel compound FLZ alleviates rotenone-induced PD mouse model by suppressing TLR4/MyD88/NF-
    Zhao Z; Li F; Ning J; Peng R; Shang J; Liu H; Shang M; Bao XQ; Zhang D
    Acta Pharm Sin B; 2021 Sep; 11(9):2859-2879. PubMed ID: 34589401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut Microbiota: A Novel Therapeutic Target for Parkinson's Disease.
    Zhu M; Liu X; Ye Y; Yan X; Cheng Y; Zhao L; Chen F; Ling Z
    Front Immunol; 2022; 13():937555. PubMed ID: 35812394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut microbiota defined epigenomes of Alzheimer's and Parkinson's diseases reveal novel targets for therapy.
    Nohesara S; Abdolmaleky HM; Thiagalingam S; Zhou JR
    Epigenomics; 2024 Jan; 16(1):57-77. PubMed ID: 38088063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuro-Immunity and Gut Dysbiosis Drive Parkinson's Disease-Induced Pain.
    Roversi K; Callai-Silva N; Roversi K; Griffith M; Boutopoulos C; Prediger RD; Talbot S
    Front Immunol; 2021; 12():759679. PubMed ID: 34868000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut-directed therapy in Parkinson's disease.
    Benvenuti L; Di Salvo C; Bellini G; Seguella L; Rettura F; Esposito G; Antonioli L; Ceravolo R; Bernardini N; Pellegrini C; Fornai M
    Front Pharmacol; 2024; 15():1407925. PubMed ID: 38974034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson's Disease.
    Caputi V; Giron MC
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29882798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Gut-Brain Axis: Two Ways Signaling in Parkinson's Disease.
    Dogra N; Mani RJ; Katare DP
    Cell Mol Neurobiol; 2022 Mar; 42(2):315-332. PubMed ID: 33649989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain-gut-microbiota axis in Parkinson's disease: A historical review and future perspective.
    Dong S; Sun M; He C; Cheng H
    Brain Res Bull; 2022 Jun; 183():84-93. PubMed ID: 35245613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrointestinal dysfunction in Parkinson's disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation.
    Metta V; Leta V; Mrudula KR; Prashanth LK; Goyal V; Borgohain R; Chung-Faye G; Chaudhuri KR
    J Neurol; 2022 Mar; 269(3):1154-1163. PubMed ID: 33881598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF-α signaling pathway.
    Sun MF; Zhu YL; Zhou ZL; Jia XB; Xu YD; Yang Q; Cui C; Shen YQ
    Brain Behav Immun; 2018 May; 70():48-60. PubMed ID: 29471030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Research Progress of Microbiota-Gut-Brain Axis in Parkinson's Disease.
    Zhang W; Ye Y; Song J; Sang T; Xia T; Xie L; Qiu X; Zeng Q; Luo X
    J Integr Neurosci; 2023 Oct; 22(6):157. PubMed ID: 38176929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain-gut-microbiota axis in Parkinson's disease.
    Mulak A; Bonaz B
    World J Gastroenterol; 2015 Oct; 21(37):10609-20. PubMed ID: 26457021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease.
    Cui C; Han Y; Li H; Yu H; Zhang B; Li G
    Front Cell Infect Microbiol; 2022; 12():887407. PubMed ID: 36034698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microbiota-mediated effects of Parkinson's disease medications on Parkinsonian non-motor symptoms in male transgenic mice.
    Radisavljevic N; Metcalfe-Roach A; Cirstea M; Tabusi MM; Bozorgmehr T; Bar-Yoseph H; Finlay BB
    mSphere; 2024 Jan; 9(1):e0037923. PubMed ID: 38078745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging insights between gut microbiome dysbiosis and Parkinson's disease: Pathogenic and clinical relevance.
    Bi M; Feng L; He J; Liu C; Wang Y; Jiang H; Liu SJ
    Ageing Res Rev; 2022 Dec; 82():101759. PubMed ID: 36243356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.